Delayed-release agents

P. C. Harris and S. J. Heath. Delayed release borate crosslinking agent. Patent EP 594364, 1994. 

A polyacetylene coating applied on sulfur does not negatively influence its activity and speed as curing agent, but it can increase the scorch time. This effect is probably due to a delayed release of the sulfur out of the polymeric shell. In the SBR/EPDM blend, on the other hand, the plasma-treated sulfur results in higher torque values, an indication that the distribution of the plasma-treated sulfur over the different rubber phases is more homogenous, which is the main effect aimed for in the context of this study. 

Oral 20 mg delayed-release tablets Mucosal Protective Agents Misoprostol (Cytotec)... 

Spermatids Few agents have been specifically implicated in spermatid toxicity. Exposure to methyl chloride (once used as a fumigant) caused a delayed release of mature spermatids from the testis. In addition, spermatids were present at much later stages than would be expected. Another discontinued fumigant, ethylene dibromide, also directly affects spermatids, although other germ cell types were also affected. 

Valproic Acid. Valproic acid (VPA), is available in several chemical forms, including valproic acid, sodium valproate, and divalproex sodium, a stable coordination compound containing equal proportions of valproic acid and sodium valproate. In either of these forms, the dosage is expressed as valproic acid equivalents (Table 6.1) (18).Oral valproic acid derivatives are rapidly absorbed the absolute bioavailability of divalproex extended-release (ER) tablets was about 90% relative to that of the intravenous infusion. The ER form had an average bioavailability of 81 -89%compared to that of divalproex delayed-release tablets given twice daily. The relationship between plasma concentration and clinical response is not clear. This may be attributed to the nonlinear concentration-dependent protein binding of valproic acid, which in turn affects the clearance of the agent (18). 

The only current treatment of EHEC infection is supportive, including fluid and electrolyte replacement, often in the form of ORT. Most illnesses resolve in 5 to 7 days. Patients should be monitored for the development of HUS. Antibiotics are currently contraindicated because they can induce the expression and release of toxin. Antimotility agents should be avoided because they may delay clearance of the pathogen and toxin. This, in turn, may increase the risk of systemic complications. 

---